LIX1L

Across TCGA pan-cancer cohorts, LIX1L mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated LIX1L data layer compared with 20 for mass-spec protein and 4 for mutation status.

The strongest signal is observed in uterine corpus endometrial carcinoma (UCEC), where higher LIX1L mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated LIX1L expression acts as an unfavorable survival marker, although some lineages such as GBM and CCRCC show a favorable association.

UCEC, PDAC, and GBM are the cancer types where LIX1L mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
UCEC	OS	Tertile	II,III,IV	0.553	1.000	.022	14	view →
PDAC	DFS	Quartile	III,IV	0.159	0.892	.005	14	view →
GBM	OS	Tertile	All	0.500	0.270	.007	7	view →
CCRCC	OS	Median	IV	1.000	0.202	.034	6	view →
LSCC	DFS	Tertile	II,III,IV	0.844	1.000	.035	3	view →
LUAD	DFS	Tertile	All	0.804	0.568	.032	2	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

LIX1L–UCEC (OS)

Open the UCEC breakdown →